Organogenesis Financial Statements From 2010 to 2025

ORGO Stock  USD 4.66  0.11  2.31%   
Organogenesis Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Organogenesis Holdings' valuation are provided below:
Gross Profit
348 M
Profit Margin
(0.03)
Market Capitalization
605.1 M
Enterprise Value Revenue
1.5142
Revenue
458.8 M
We have found one hundred twenty available trending fundamental ratios for Organogenesis Holdings, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Organogenesis Holdings' recent fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 30th of July 2025, Market Cap is likely to grow to about 696.8 M, while Enterprise Value is likely to drop about 312.6 M.

Organogenesis Holdings Total Revenue

272.69 Million

Check Organogenesis Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organogenesis Holdings' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 1.5 M or Selling General Administrative of 165 M, as well as many indicators such as Price To Sales Ratio of 0.83, Dividend Yield of 0.0034 or PTB Ratio of 1.04. Organogenesis financial statements analysis is a perfect complement when working with Organogenesis Holdings Valuation or Volatility modules.
  
Build AI portfolio with Organogenesis Stock
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Organogenesis Holdings Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets315.7 M497.9 M217.1 M
Slightly volatile
Total Current Liabilities51.5 M77.5 M35.5 M
Slightly volatile
Other Liabilities1.2 M1.3 MM
Very volatile
Accounts Payable24.6 M28.9 M19.2 M
Slightly volatile
Cash142.3 M135.6 M47.9 M
Slightly volatile
Other Assets1.091.154.5 M
Slightly volatile
Long Term Debt65.7 M69.9 M65 M
Pretty Stable
Net Receivables59.6 M109.9 M43.5 M
Slightly volatile
Short Term Investments146.2 K173.7 K149.9 K
Slightly volatile
Inventory21.6 M26.2 M17.8 M
Slightly volatile
Other Current Assets15 M14.3 MM
Slightly volatile
Total Liabilities114 M112.6 M78.5 M
Slightly volatile
Total Current Assets300.2 M285.9 M102.2 M
Slightly volatile
Common Stock11.1 K11.7 K36.8 M
Very volatile
Property Plant Equipment123.7 M117.8 M61.8 M
Slightly volatile
Short and Long Term Debt Total81.1 M43.3 M46.6 M
Slightly volatile
Non Current Assets Total200.3 M211.9 M126.4 M
Slightly volatile
Non Currrent Assets Other4.8 MM40.3 M
Very volatile
Cash And Short Term Investments68.6 M135.6 M43.3 M
Slightly volatile
Common Stock Shares Outstanding103.3 M131.7 M84.9 M
Slightly volatile
Liabilities And Stockholders Equity346.9 M497.9 M218.9 M
Slightly volatile
Non Current Liabilities Total68.3 M35.1 M43.2 M
Slightly volatile
Capital Surpluse182.7 M357.6 M136.3 M
Slightly volatile
Non Current Liabilities Other849.3 K894 K154.5 M
Slightly volatile
Net Invested Capital275.1 M262.9 M272.7 M
Very volatile
Property Plant And Equipment Net110.5 M126.2 M70.7 M
Slightly volatile
Current Deferred Revenue30.6 M41.1 M31.1 M
Slightly volatile
Long Term Debt Total76.6 M76.2 M60.1 M
Slightly volatile
Capital Lease Obligations40.6 M43.3 M27.5 M
Slightly volatile
Property Plant And Equipment Gross133.5 M199.2 M81.3 M
Slightly volatile
Capital Stock128.6 M122.4 M15.7 M
Slightly volatile

Organogenesis Holdings Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative165 M294.5 M113.4 M
Slightly volatile
Research Development52.8 M50.3 M18.7 M
Slightly volatile
Cost Of Revenue72.6 M115.7 M61.5 M
Slightly volatile
Total Operating Expenses222.9 M367.6 M184.4 M
Slightly volatile
Interest Income10.9 M10.3 M5.4 M
Slightly volatile
Reconciled Depreciation15.2 M17 M10.5 M
Slightly volatile
Selling And Marketing Expenses4.3 MM2.4 M
Slightly volatile

Organogenesis Holdings Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation12 M17 M10.2 M
Slightly volatile
Capital Expenditures13.4 M10 M9.3 M
Slightly volatile
End Period Cash Flow143 M136.2 M48.5 M
Slightly volatile
Stock Based Compensation11.1 M10.6 M3.1 M
Slightly volatile
Begin Period Cash Flow54.3 M104.3 M34.5 M
Slightly volatile
Cash Flows Other Operating14.6 M19.6 M7.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.830.87412.6831
Slightly volatile
Dividend Yield0.00340.00380.0042
Slightly volatile
PTB Ratio1.041.09353.4527
Very volatile
Days Sales Outstanding53.6783.186164.8545
Pretty Stable
Book Value Per Share2.572.92633.2558
Slightly volatile
Stock Based Compensation To Revenue0.0230.02190.0092
Slightly volatile
Capex To Depreciation0.780.58920.6834
Slightly volatile
PB Ratio1.041.09353.4527
Very volatile
EV To Sales0.650.68272.7877
Slightly volatile
Inventory Turnover4.54.41444.6518
Slightly volatile
Days Of Inventory On Hand10182.684181.8087
Slightly volatile
Payables Turnover2.494.00341.8143
Slightly volatile
Sales General And Administrative To Revenue0.680.70.7085
Slightly volatile
Research And Ddevelopement To Revenue0.06080.10430.0648
Slightly volatile
Capex To Revenue0.0360.02080.0267
Slightly volatile
Cash Per Share1.081.02960.4024
Slightly volatile
Payout Ratio1.671.882.0491
Slightly volatile
Days Payables Outstanding86.6191.1735809
Slightly volatile
Income Quality17.3316.50173.1236
Slightly volatile
Intangibles To Total Assets0.07870.08280.2339
Slightly volatile
Current Ratio3.883.69071.6699
Slightly volatile
Receivables Turnover6.074.38785.6334
Pretty Stable
Graham Number0.620.65622.1776
Pretty Stable
Shareholders Equity Per Share2.572.92633.2558
Slightly volatile
Capex Per Share0.0960.07620.0838
Slightly volatile
Revenue Per Share2.613.66092.9925
Slightly volatile
Interest Debt Per Share0.590.34070.4844
Slightly volatile
Debt To Assets0.08260.0870.2895
Slightly volatile
Operating Cycle127166145
Slightly volatile
Price Book Value Ratio1.041.09353.4527
Very volatile
Days Of Payables Outstanding86.6191.1735809
Slightly volatile
Dividend Payout Ratio1.671.882.0491
Slightly volatile
Ebt Per Ebit2.32.18780.878
Slightly volatile
Long Term Debt To Capitalization0.350.210.3821
Slightly volatile
Total Debt To Capitalization0.0960.1010.5465
Slightly volatile
Quick Ratio3.523.35221.5027
Slightly volatile
Cash Ratio1.841.74980.8891
Slightly volatile
Days Of Inventory Outstanding10182.684181.8087
Slightly volatile
Days Of Sales Outstanding53.6783.186164.8545
Pretty Stable
Price To Book Ratio1.041.09353.4527
Very volatile
Fixed Asset Turnover4.623.81854.566
Slightly volatile
Debt Ratio0.08260.0870.2895
Slightly volatile
Price Sales Ratio0.830.87412.6831
Slightly volatile
Asset Turnover1.180.96821.1323
Slightly volatile
Gross Profit Margin0.580.75990.6792
Slightly volatile
Price Fair Value1.041.09353.4527
Very volatile

Organogenesis Holdings Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap696.8 M421.4 M631 M
Very volatile
Enterprise Value312.6 M329.1 M609.1 M
Pretty Stable

Organogenesis Fundamental Market Drivers

Forward Price Earnings12.3153
Cash And Short Term Investments135.6 M

Organogenesis Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Organogenesis Holdings Financial Statements

Organogenesis Holdings investors utilize fundamental indicators, such as revenue or net income, to predict how Organogenesis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue41.1 M30.6 M
Total Revenue482 M272.7 M
Cost Of Revenue115.7 M72.6 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.70  0.68 
Research And Ddevelopement To Revenue 0.10  0.06 
Capex To Revenue 0.02  0.04 
Revenue Per Share 3.66  2.61 

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Organogenesis Stock

  0.37BKRKF PT Bank RakyatPairCorr
  0.34ERNA Eterna TherapeuticsPairCorr
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
3.5
Earnings Share
(0.16)
Revenue Per Share
3.521
Quarterly Revenue Growth
(0.21)
Return On Assets
0.007
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.